Potential nootropic agents, 4-alkoxy-2-(1-piperazinyl)quinazoline derivatives.
A series of 4-alkoxy-2-(1-piperazinyl)quinazoline derivatives was synthesized and evaluated for its ability to reverse a scopolamine-induced learned impairment in a one-trial passive avoidance task (antiamnestic activity). 2-(4-Allyl-1-piperazinyl)-4-pentyloxyquinazoline (4) showed more potent antiamnestic activity than such reference compounds as aniracetam, idebenone and bifemelane at a wide dose range (1-30 mg/kg]. Compound 4 also exhibited potent anticonvulsive and antihypoxic activities, and was selected as the most promising nootropic candidate agent.
Hori
M
M
Pharmaceuticals Research Center, Kanebo Ltd., Osaka, Japan.
Iemura
R
R
Hara
H
H
Sukamoto
T
T
Ito
K
K
Ohtaka
H
H
D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects; D051379:Mice; D008815:Mice, Inbred Strains; D010879:Piperazines / Q000138:chemical synthesis* / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000138:chemical synthesis*; D011799:Quinazolines / Q000138:chemical synthesis* / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains
D010879:Piperazines; D011619:Psychotropic Drugs; D011799:Quinazolines; C069417:2-(4-allyl-1-piperazinyl)-4-pentyloxyquinazoline